MedTrace Logo

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

NCT06992713 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-07-23

No results posted yet for this study

Summary

This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

H1710 for Injection

Injection.

Sponsors & Collaborators

  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-18
Primary Completion
2026-09-04
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06992713 on ClinicalTrials.gov